Orthofix Medical (NASDAQ:OFIX) Posts Quarterly Earnings Results, Misses Expectations By $0.40 EPS

Key Points

• Orthofix Medical reported a quarterly EPS of ($0.36), missing analysts' estimates by $0.40 and reflecting a negative return on equity of 28.15% and net margin of 17.78%.
• The company's stock, trading at $12.18, has seen a rise of 12.2% recently, while analysts maintain a consensus target price of $21.50 and a "Moderate Buy" rating.
• Insider trading activity included a sale of 3,728 shares by a company insider and a purchase of 10,000 shares by CEO Massimo Calafiore, indicating mixed confidence among company insiders.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) released its quarterly earnings data on Tuesday. The medical device company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.40), Zacks reports. The business had revenue of $203.12 million for the quarter, compared to analyst estimates of $196.89 million. Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%. Orthofix Medical updated its FY 2025 guidance to EPS.

Orthofix Medical Stock Performance

NASDAQ OFIX traded down $0.19 on Friday, hitting $12.51. The stock had a trading volume of 453,385 shares, compared to its average volume of 333,042. The company's 50-day moving average is $11.12 and its two-hundred day moving average is $13.90. The company has a quick ratio of 1.50, a current ratio of 2.67 and a debt-to-equity ratio of 0.38. The stock has a market cap of $490.14 million, a price-to-earnings ratio of -3.95 and a beta of 0.82. Orthofix Medical has a one year low of $10.24 and a one year high of $20.73.

Insider Activity

In other news, insider Aviva Mcpherron sold 3,728 shares of the stock in a transaction that occurred on Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total value of $39,181.28. Following the completion of the transaction, the insider directly owned 46,322 shares in the company, valued at $486,844.22. This trade represents a 7.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio bought a new stake in Orthofix Medical during the first quarter worth approximately $150,000. Jane Street Group LLC bought a new stake in Orthofix Medical during the first quarter worth approximately $1,076,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Orthofix Medical by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company's stock worth $335,000 after buying an additional 1,213 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company's stock worth $333,000 after buying an additional 8,241 shares in the last quarter. 89.76% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. JMP Securities reiterated a "market perform" rating on shares of Orthofix Medical in a research note on Friday, June 6th. Barrington Research upgraded shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 target price for the company in a research report on Monday, June 23rd. Finally, Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Saturday. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $21.50.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.